B+
Bull case
25%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-08-10 · RankAlpha Sentiment Codex
INCY
IncyteBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$128.00
Analysis reference price unavailable
Analysis 2026-08-10 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$102.00
Analysis reference price unavailable
Analysis 2026-08-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-10
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+64.6
Score
AI commentary
News tone is positive following the Q2 results, raised guidance, and Opzelura EU headline, but the immediate market reaction was mixed in the packet: strong performance on the earnings date followed by a retreat the next day. Analyst revisions, options data, short interest, employee sentiment, and sufficient social coverage are unavailable; peer comparisons are therefore qualitative only.
RankAlpha Sentiment Codex - 2026-08-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-28catalystQ2 beat-and-raise supports near-term sentimentMedium impact
Incyte reported Q2 revenue of $1.67 billion and net sales of $1.49 billion, while raising 2026 total-sales guidance to $5.13-$5.26 billion and Opzelura guidance to $1.05-$1.10 billion. The comparison is moderated by a $246 million one-time Opzelura benefit. [#SEC-8K-2026-07-28]
2026-10-23catalystDated ESMO oncology data readoutsMedium impact
Incyte expects rapid oral presentations at the 2026 ESMO Congress, October 23-27, covering INCB161734 in pancreatic and colorectal cancer, INCA33890 in microsatellite-stable colorectal cancer, and INCB123667 in ovarian cancer. [#SEC-8K-2026-07-28]
2026-11-08eventOpzelura hidradenitis suppurativa topline dataMedium impact
Topline results from the Phase 3 TRuE-HS1 and TRuE-HS2 studies evaluating ruxolitinib cream in mild-to-moderate hidradenitis suppurativa are anticipated in Q4 2026. [#SEC-8K-2026-07-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-10 • Updated nightlySource: Internal modelMethodology